Get App Open
In App
Lending
Lending
Open App

UTI Healthcare Fund - Direct Plan - IDCW

  • Regular
  • Direct
Category : Sectoral/Thematic
Fund House : UTI Mutual Fund
  • NAV
    : ₹ 254.1187 -0.71%
    (as on 06th November, 2025)
Crisil Rating

Not Rated

Rank not available for the fund
Risk-O-Meter
Very High Risk

The fund has 98.99% investment in domestic equities of which 24.85% is in Large Cap stocks, 17.53% is in Mid Cap stocks, 18.77% in Small Cap stocks.

Suitable For : Investors who have advanced knowledge of macro trends and prefer to take selective bets for higher returns compared to other Equity funds. At the same time, these investors should also be ready for possibility of moderate to high losses in their investments even though overall market is performing better.

This Scheme
VS
  • Benchmark
    BSE Healthcare TRI
  • NA
  • NA
  • Gold
Compare with
  • Date : -
  • NAV : -
  • Date : -
  • Investment : -
  • Value on selected date : -
  • Returns Calculator
  • SIP Calculator
  • VIP (Value Avg)
Amount
  • Investment Date
  • Sell Date
  • Investment Value
    -
  • Sell Value
    -
  • Profit/Loss
    -
  • Annualised Returns
    -
  • Date : -
  • Investment : -
  • Value on selected date : -

Returns (NAV as on 06th November, 2025)

Period Invested for ₹10000 Invested on Latest Value Absolute Returns Annualised Returns Category Avg Rank within Category
1 Week 30-Oct-25 9945.00 -0.55% - -1.28% 32/229
1 Month 06-Oct-25 10054.70 0.55% - 0.99% 146/226
3 Month 06-Aug-25 10173.90 1.74% - 4.17% 201/224
6 Month 06-May-25 10885.10 8.85% - 10.10% 114/213
YTD 01-Jan-25 9979.50 -0.20% - 4.45% 136/201
1 Year 06-Nov-24 10083.90 0.84% 0.84% 2.84% 115/187
2 Year 06-Nov-23 16204.90 62.05% 27.26% 20.77% 15/141
3 Year 04-Nov-22 19234.40 92.34% 24.29% 20.15% 25/117
5 Year 06-Nov-20 23618.50 136.19% 18.74% 22.87% 70/93
10 Year 06-Nov-15 33526.50 235.27% 12.85% 15.45% 54/65
Since Inception 02-Jan-13 68904.20 589.04% 16.20% 13.84% 89/199

SIP Returns (NAV as on 06th November, 2025)

Period Invested for ₹1000 SIP Started on Investments Latest Value Absolute Returns Annualised Returns
1 Year 06-Nov-24 12000 12516.11 4.3 % 8.02 %
2 Year 06-Nov-23 24000 28054.96 16.9 % 15.76 %
3 Year 04-Nov-22 36000 50710.94 40.86 % 23.51 %
5 Year 06-Nov-20 60000 98653.76 64.42 % 19.96 %
10 Year 06-Nov-15 120000 312185.94 160.15 % 18.17 %
 

Tax Treatment

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not included. If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 20%. Any cess/surcharge is not included in the 20%.

Portfolio (Updated on 30th Sep,2025)

Portfolio Turnover Ratio : 32.00%  |   Category average turnover ratio is 203.09%  
Fund manager updated portfolio less frequently than peers in last 1 year. (I.e. fund manager held stocks/bonds in the portfolio for longer duration than peers)
Equity Holding : 98.99% | F&O Holdings : 0.00%| Foreign Equity Holdings : 0.00%| Total : 98.99%
No of Stocks : 41 (Category Avg - 44.42) | Large Cap Investments : 24.85%| Mid Cap Investments : 17.53% | Small Cap Investments : 18.77% | Other : 37.84%

Top 10 Stocks in Portfolio

How to read this table?
Stock Invested in Sector Value(Mn) % of Total Holdings 1M Change 1Y Highest Holding 1Y Lowest Holding Quantity 1M Change in Qty
Sun Pharmaceutical Industries Ltd. Pharmaceuticals 1053.9 9.61% 0.19% 11.88% (Apr 2025) 9.42% (Aug 2025) 6.61 L 0.00
Ajanta Pharma Limited Pharmaceuticals 601.6 5.48% 0.10% 5.48% (Sep 2025) 4.09% (May 2025) 2.50 L 7.33 k
Cipla Ltd. Pharmaceuticals 601.3 5.48% -0.20% 6.19% (Feb 2025) 5.43% (Jul 2025) 4.00 L 0.00
Lupin Ltd. Pharmaceuticals 516.1 4.70% 0.13% 4.7% (Sep 2025) 0% (Oct 2024) 2.70 L 0.00
- Procter & Gamble Health Ltd. Pharmaceuticals 437.2 3.99% 0.00% 4.34% (May 2025) 3.14% (Dec 2024) 69.32 k -0.72 k
Glenmark Pharmaceuticals Ltd. Pharmaceuticals 410.1 3.74% -0.04% 4.07% (Mar 2025) 3.54% (Jul 2025) 2.10 L -0.10 L
Dr. Reddys Laboratories Ltd. Pharmaceuticals 409.9 3.74% -0.32% 5.28% (Dec 2024) 3.74% (Sep 2025) 3.35 L -0.25 L
Gland Pharma Ltd. Pharmaceuticals 396.9 3.62% 0.29% 3.85% (Nov 2024) 2.43% (Apr 2025) 1.99 L 0.00
Apollo Hospitals Enterprises Ltd. Hospital 392.7 3.58% -0.03% 3.78% (Apr 2025) 3.22% (Feb 2025) 53.00 k 0.00
Alkem Laboratories Ltd. Pharmaceuticals 390.6 3.56% 0.15% 3.56% (Sep 2025) 1.92% (May 2025) 72.00 k 0.00
- indicates change in weight in the portfolio. # indicates a new entry.
Name Type of Instrument Weight (%)
Net Receivables Net Receivables 1.00%
Margin Margin 0.01%

Risk Ratios

Ratios calculated on daily returns for last 3 years (Updated as on 31st October, 2025)

  • Standard Deviation

    Low volatility
    12.41vs13.95
    Category Avg
  • Beta

    Low volatility
    0.61vs0.86
    Category Avg
  • Sharpe Ratio

    Better risk adjusted returns
    1.32vs0.91
    Category Avg
  • Treynor's Ratio

    Better risk adjusted returns
    0.27vs0.17
    Category Avg
  • Jensen's Alpha

    Better risk adjusted returns
    11.32vs3.58
    Category Avg

Alternative Funds (Category Peers)

Scheme Name
Crisil Rank
Asset Size (Cr)
1M
3M
6M
1Y
3Y
Nippon India Taiwan Equity Fund - Direct Plan - Growth NA 406.67 1.52 24.35 61.47 45.03 41.90
Aditya Birla Sun Life International Equity Fund - Direct Plan - Growth NA 266.19 -1.39 4.64 20.48 28.76 18.93
Nippon India Japan Equity Fund - Direct Plan - Growth NA 289.73 -0.94 6.74 17.93 22.02 20.35
Franklin Asian Equity Fund - Direct - Growth NA 279.13 2.25 12.39 24.69 21.55 17.31
HDFC Transportation and Logistics Fund - Direct Plan - Growth NA 1651.55 -0.13 10.94 26.44 18.75 0.00
Quant BFSI Fund - Direct Plan - Growth NA 655.17 2.41 5.42 21.39 16.51 0.00
DSP Banking & Financial Services Fund - Direct Plan - Growth NA 1419.62 2.30 6.59 10.36 15.94 0.00
ITI Banking and Financial Services Fund - Direct Plan - Growth NA 311.03 3.61 6.95 9.73 15.89 15.61
SBI Banking & Financial Services Fund - Direct Plan - Growth NA 8693.07 1.94 5.57 11.70 14.86 20.45
Mirae Asset Banking and Financial Services Fund - Direct Plan - Growth NA 2014.27 3.03 5.08 10.20 13.32 18.93

More Funds from UTI Mutual Fund

Out of 71 mutual fund schemes offered by this AMC, 4 is/are ranked 4 * , 12 is/are ranked 3 * , 9 is/are ranked 2 * , 3 is/are ranked 1 * , and 43 schemes are not ranked. See more about AMC

Scheme Name
Crisil Rank
Asset Size (Cr)
1M
3M
6M
1Y
3Y
UTI Flexi Cap Fund - Direct Plan - Growth 2 25187.42 1.59 1.89 6.06 5.13 11.54
UTI Nifty 50 Index Fund - Direct Plan - Growth 3 24335.81 2.91 3.76 6.01 7.79 13.23
UTI Liquid Fund - Direct Plan - Growth 2 21945.52 0.48 1.46 3.05 6.78 7.09
UTI Money Market Fund - Direct Plan - Growth 2 18862.20 0.50 1.48 3.45 7.75 7.69
UTI Large Cap Fund - Direct Plan - Growth 3 12946.56 2.14 3.43 5.51 6.99 13.28
UTI Mid Cap Fund - Direct Plan - Growth 2 11666.34 2.93 3.15 12.37 3.18 17.54
UTI Value Fund - Direct Plan - Growth 3 9726.59 2.20 3.54 7.97 4.80 18.92
UTI Arbitrage Fund - Direct Plan - Growth 4 9167.09 0.63 1.52 3.15 7.17 7.75
UTI Nifty200 Momentum 30 Index Fund - Direct Plan - Growth NA 8204.04 4.09 4.16 7.96 -7.76 16.39
UTI Overnight Fund - Direct Plan - Growth NA 6558.86 0.46 1.36 2.76 6.02 6.44

Forum

+ See More

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347